The anticancer effect of RAD51-IN-1 in MDAH-2774 (CVCL_0420) cells

Aim. This study aimed to investigate the effect of pharmacological inhibition of RAD51, via RAD51-IN-1, on the MDAH-2774 cell line Methods. To achieve these objectives, MDAH-2774 cells were treated with different doses of RAD51-IN-1 to determine the effects on cell viability and the IC50 value of RAD51-IN-1. Intracellular ROS levels of the cells were investigated by DCFDA staining. In the last set of experiments, the effect of RAD51-IN-1 monotherapy application on apoptotic cell death was investigated by acridine orange/ ethidium bromide staining. Results. In the experimental findings obtained, firstly, cells were treated with different doses of RAD51-IN-1 to decrease cell viability and IC50 of RAD51-IN-1 was determined. In addition, it was observed that the amount of intracellular ROS increased after DCFDA staining after RAD51-IN-1 treatment. In the last set of experiments, it was determined that cell death occurred with increasing doses f of RAD51-IN-1. Conclusion. The RAD51-IN-1 small molecule inhibitor is a promising approach for treating ovarian cancer, but the drug requires further in vitro evaluation.